Skip to main content
An official website of the United States government
Email

Biological Testing Branch (BTB)

Kaplan-Meier curve

The Biological Testing Branch (BTB) of the Developmental Therapeutics Program (DTP), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI) operates out of the National Cancer Institute at Frederick providing budgetary oversight and technical direction for an extensive contractual effort designed to discover chemotherapeutic agents for cancer. Specifically, BTB’s missions are five-fold:

  • develop and maintain a repository of Patient-Derived Models (PDMs) comprised of patient-derived xenografts (PDXs) and in vitro patient-derived cell cultures (PDCs), including mixed cell populations, clonal cell lines, and fibroblast cell lines;
  • maintain a repository of experimental animal and human tumor cell lines for use in research performed by the Program and other qualified investigators;
  • plan, direct and implement a contract-supported program to screen compounds for indications of in vivo preclinical efficacy including single agent and combination therapies;
  • provide in vivo resources for preclinical pharmacologic and pharmacodynamic studies in support of drug development;
  • develop new screening models.

BTB Contact Information

Biological Testing Branch
DTP, DCTD, NCI
P.O. Box B, Bldg 1066, Room 101B
Frederick, MD 21702
 

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Biological Testing Branch (BTB) was originally published by the National Cancer Institute.”

Email